MiMedx Securities Enforcement Case: The Invoice Said Sold, the Customer Had Other Terms

In the MiMedx securities enforcement case, the SEC announced a proposed $1.5 million company penalty in November 2019 over allegations of premature revenue recognition and concealed distributor terms. The SEC alleged that the company counted shipments as sales while customers had promises allowing them to wait for resale, return products or exchange goods they never wanted. If you handled those orders, credits or payments, you may recognize the difference between the sale accounting recorded and the deal the customer understood.

The SEC’s complaint described more than $1 billion in shareholder value lost during the disclosures. We see a proposed company penalty dwarfed by the loss investors bore.

This page follows MiMedx’s distributor transactions and the internal records behind the revenue investors saw. Our broader page on side agreements and bill-and-hold sales explains how undisclosed terms can change the accounting. Here, the complaint’s most revealing details concern the work employees allegedly did to keep the undisclosed arrangements running.

What the SEC Alleged About MiMedx’s Revenue

The Securities and Exchange Commission’s complaint against MiMedx and three former executives alleged a scheme running from 2013 through the third quarter of 2017 involving five distributors. The defendants included the company, its former chairman and CEO, its former president and chief operating officer, and its former chief financial officer. The SEC brought the action in the Southern District of New York.

MiMedx manufactured and sold products derived from human placental, amniotic and umbilical tissues through its sales force, agents and distributors. Its products included EpiFix and AmnioFix tissue grafts for wound care and surgery, and an injectable amniotic liquid sold as OrthoFlo. The distinction between shipping those products and earning revenue from them sat at the center of the complaint.

MiMedx disclosed different accounting for direct sales and consignment. For consignment customers, the company said it recognized revenue when the product was used or implanted, because shipment left payment conditional and the risk of loss with MiMedx. The SEC alleged that executives concealed terms that made purported direct sales resemble those consignment arrangements. A shipment could reach the hospital while the customer’s obligation to pay remained unfinished.

Four Distributor Deals Behind the Reported Growth

As sales to its largest distributor declined, the SEC alleged, MiMedx’s CEO and chief operating officer arranged additional transactions with four other distributors. Each arrangement changed something accounting needed to know: when payment became due, which products the customer accepted, where the customer’s money came from or whether the goods could come back.

Distributor A’s Payment Depended on Government Approval

Distributor A sold MiMedx products to government-run medical facilities in Saudi Arabia and needed procurement authorization from the Saudi Ministry of Health. The SEC alleged that MiMedx booked approximately $1.9 million of revenue on an order whose payment depended on that authorization and resale. When accounting questioned the terms, the chief operating officer allegedly said the authorization had already arrived and the payment deadline was fixed.

The complaint described a later order with a particularly clear email trail. It alleged that, after accounting requested fixed payment terms, the chief operating officer sent the distributor a separate promise of more time, help selling the goods or repurchase if the government authorization was delayed. The revised purchase order showed a fixed payment period, but the SEC alleged that the executive kept the separate promise from accounting and the auditor. The revised order tidied up the deadline. The other email kept the escape route.

Distributor B Bought What MiMedx Could Ship

The SEC alleged that MiMedx paid Distributor B’s principal $200,000 to induce an order and recorded the payment as a consulting expense, even though the principal performed no additional services for it. The complaint said the payment should have reduced revenue from the sale. Calling it consulting kept that reduction out of the sales number.

The products created another mismatch. Distributor B wanted a mix MiMedx could not ship before the quarter closed, so the SEC alleged that MiMedx persuaded it to accept available inventory and exchange unwanted products afterward. The complaint attributed approximately $1.2 million of premature revenue to those unwanted goods. For someone in sales or fulfillment, the original order, revised order and promised exchange explain why a box leaving the warehouse did not finish the bargain.

Distributor C’s Payment Came From the CEO’s Family

Distributor C was a new distributor with limited capital, yet the SEC alleged that MiMedx booked approximately $4.6 million of revenue from its orders, primarily for OrthoFlo. The written agreement called for payment within thirty days. According to the complaint, the CEO and chief operating officer privately promised flexibility and allowed exchanges between vial sizes.

The product itself made the distributor’s capacity relevant. OrthoFlo required specialized freezers, and the complaint said MiMedx supplied them because Distributor C lacked the capital to buy them. The SEC alleged that, when the distributor could not pay its invoices and had been refused a commercial loan, the CEO’s family supplied financing through a newly formed limited liability company.

The SEC alleged that the distributor used that financing to make its first substantial payments to MiMedx. The CEO then treated those payments as reassurance that more goods could be shipped while withholding the financing arrangement from accounting and the auditor. The bank receipt showed money arriving. The loan documents showed whose money made that possible.

Distributor D Received a Return Letter With an Earlier Date

The SEC alleged that MiMedx recognized approximately $2.2 million of revenue from Distributor D even though the parties had not agreed on their distribution terms by quarter-end. Distributor D also allegedly accepted unwanted vial sizes with permission to exchange them later. According to the complaint, the stated payment deadline differed from what the executives and distributor understood would actually be required.

The SEC alleged that the CEO sent a return letter on December 31, 2015, dated September 25, 2015. It promised exchanges or returns if acquisition talks failed and the distributor wanted to pursue its own products. The SEC said the CEO withheld the letter from accounting and the auditor, and MiMedx recognized another $450,000 of revenue on a subsequent order. In the SEC’s account, even the return promise got an earlier date.

Distributor E’s Payments Followed the VA’s Purchases

Distributor E supplied Veterans Affairs and Defense Department medical facilities and was MiMedx’s largest customer for much of the relationship. The complaint put its share of MiMedx’s reported revenue at 56% in 2013, 34% in 2014 and 24% in 2015. That concentration made the alleged difference between the written contract and actual payment practice central to the company’s reported results.

The written distribution agreement treated the transactions as direct sales, with title and risk passing at shipment and payment due after the invoice. The SEC alleged that the actual arrangement let Distributor E wait for payment from the VA and receive credits for dropped, damaged or missing products and unwanted returns. MiMedx continued recognizing revenue at shipment even though, according to the complaint, it retained the risk and the arrangement operated as consignment.

The complaint quoted a March 2013 email from the chief operating officer acknowledging the payment practice. His description put the departure from the contract in the company’s own words:

Weekly Tables Explained the Cash Receipts

According to the SEC, Distributor E sent weekday reports identifying products covered by VA purchase orders, their prices and the patients on whom they had been used. A reconciliation group outside MiMedx’s accounting staff compiled the daily totals into weekly revenue tables. Distributor E’s payments matched those tables exactly, and reconciliation staff checked the match.

The alleged side arrangement therefore appeared in repeated operating records as well as an executive’s email. A controller sent the chief financial officer a weekly table and questioned what it meant:

The SEC also described early payments that MiMedx requested to improve cash flow. Those amounts were calculated under the same arrangement and offset against later payments. In the SEC’s account, the weekly tables kept the real deal. The revenue line kept the paper one.

Missing Purchase Orders Kept MiMedx Involved

MiMedx sales staff allegedly counted inventory at VA facilities each quarter and investigated missing products. Some tissue had been implanted without a VA purchase order, a category the company called “Implanted No PO.” Under the alleged arrangement, sales representatives worked with medical staff to obtain the paperwork needed for the VA to issue a purchase order before Distributor E had to pay.

The SEC alleged that MiMedx credited Distributor E for missing tissue when the purchase order could not be obtained. The complaint described similar credits for products dropped during procedures or damaged while opening packaging, as well as credits for returns. For the employee handling an inventory discrepancy, that credit showed who still bore the loss after the supposed sale.

The Questions Accounting Asked and the Answers Management Gave

The SEC alleged that a later controller challenged distributor revenue recognition and undisclosed payment terms. Management rejected the concerns, and the audit committee investigated. According to the complaint, executives withheld the side arrangements from the committee and auditors, leaving them to assess transactions without the terms that changed the accounting.

The complaint also described allegations of channel stuffing involving Distributor E, raised by two MiMedx sales employees. The SEC alleged that executives concealed the side arrangement during the audit committee investigation that followed.

According to the complaint, management also withheld the arrangements from a revenue-recognition consultant and denied side agreements in an accounting paper. In a response to SEC questions, management said distributors owed payment regardless of resale and Distributor E had only limited return rights. Those statements can be compared with the weekly payment tables, return credits and executive email.

A new auditor later questioned Distributor E’s accounting and the earlier investigations, then declined to complete its audit until the issues were investigated and resolved. MiMedx announced a filing delay and plans to restate earlier financial statements. The SEC’s complaint described an approximately 73% stock-price decline during the disclosures. Investors had been shown growth that the SEC alleged depended on concealed sales terms.

What Evidence Is Needed for Whistleblowing About MiMedx’s Sales Terms?

For alleged hidden sales terms, the useful securities fraud evidence connects the reported number to the actual transaction. In MiMedx’s case, the complaint identified purchase orders, side emails, return letters, customer payments, loan documents, inventory counts and reconciliation tables. Communications with accounting and auditors showed which terms management disclosed and which terms the SEC alleged it withheld.

The distinction also appears in the SEC’s case concerning Super Micro Computer. Its 2020 order described alleged premature revenue recognition involving freight holds, unfinished goods and delivery terms requiring products to reach their destination. MiMedx’s allegations put particular weight on the customer’s payment and return rights. Super Micro’s also exposed unfinished delivery obligations. In both, operational records explain what remained to be done when accounting recorded revenue.

The 2018 Journal of Forensic & Investigative Accounting study The Significance of Whistleblowing as an Anti-Fraud Measure found that whistleblowers detected 35.9% of the 4,943 frauds for which it had complete data, the most common detection method in its sample. That broader finding helps explain why we start with the person who understands the records. At MiMedx, the controller’s question made the payment table’s significance plain.

For an insider considering reporting securities fraud, we work with you on which transactions, reporting periods and decisions your records explain. Eligible whistleblowers can share 10% to 30% of qualifying sanctions collected in an SEC action involving more than $1 million in monetary sanctions.

If you work with sales to Veterans Affairs or Defense Department facilities and your evidence also concerns false government bills, we assess that separately with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know the Terms Behind the Sale

If you saw a customer promised one deal while accounting recorded another, speak to one of our whistleblower experts about the terms behind those sales. We connect your knowledge of the orders, credits and payments to the financial reporting, bring in securities fraud whistleblower lawyers who understand revenue recognition, and stay beside you as we build your strongest securities whistleblower case.